Discovery of Clinical Candidate AZD5462, a Selective Oral Allosteric RXFP1 Agonist for Treatment of Heart Failure-Reference-Cited by-同舟云学术

Discovery of Clinical Candidate AZD5462, a Selective Oral Allosteric RXFP1 Agonist for Treatment of Heart Failure

Published:2024-03-19 Issue:6 Volume:67 Page:4419-4441
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Granberg Kenneth L.¹^ORCID,Sakamaki Shigeki²^ORCID,Larsson Niklas³,Bergström Fredrik⁴,Fuchigami Ryuichi²,Niwa Yasuki²,Ryberg Erik⁵,Backmark Anna⁵,Kato Harutoshi²,Miyazaki Shiki²,Iguchi Kaori²,Sakamoto Toshiaki²,Persson Mikael⁶,Idei Akiko²,Prieto Garcia Luna⁴,Villar Inmaculada C.⁷,Gradén Henrik¹,Bergonzini Giulia⁸,Arvidsson Torbjörn⁹,Fujita Takuya²,Althage Magnus¹⁰,Ulander Johan¹¹,Kimura Junpei²,Yoneda Hikaru²,Fjellström Ola¹²,Mochida Hideki²,Lal Mark¹³

Affiliation:

1. Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, 431 83 Mölndal, Sweden

2. Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, 1000 Kamoshida-cho, Aoba-ku, Yokohama, Kanagawa 227−0033, Japan

3. Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg, 431 83 Mölndal, Sweden

4. Drug Metabolism and Pharmacokinetics (DMPK), Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, 431 83 Mölndal, Sweden

5. Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, 431 83 Mölndal, Sweden

6. Cardiovascular, Renal and Metabolism Safety, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, 431 83 Mölndal, Sweden

7. Regulatory Toxicology & Safety Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, Cambridge CB2 0AA, U.K.

8. Compound Synthesis and Management, Discovery Sciences, R&D, AstraZeneca, Gothenburg, 431 83 Mölndal, Sweden

9. Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, 431 83 Mölndal, Sweden

10. Translational Science and Experimental Medicine, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), Biopharmaceuticals R&D, AstraZeneca, Gothenburg, 431 83 Mölndal, Sweden

11. Data Science and Modelling, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, 431 83 Mölndal, Sweden

12. Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), Biopharmaceutical, AstraZeneca, Gothenburg, 431 83 Mölndal, Sweden

13. Bioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), Biopharmaceuticals R&D, AstraZeneca, Gothenburg, 431 83 Mölndal, Sweden

Funder

AstraZeneca

Mitsubishi Tanabe Pharma Corporation

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c02184

Reference26 articles.

1. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure

2. Prevalence, incidence and survival of heart failure: a systematic review

3. Global burden of heart failure: a comprehensive and updated review of epidemiology

4. SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials

5. Relaxin Family Peptides and Their Receptors

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic potential of relaxin or relaxin mimetics in managing cardiovascular complications of diabetes;Biochemical Pharmacology;2024-11

2. Engineering and Characterization of a Long-Half-Life Relaxin Receptor RXFP1 Agonist;Molecular Pharmaceutics;2024-08-12

3. Seleno-relaxin analogues: effect of internal and external diselenide bonds on the foldability and a fibrosis-related factor of endometriotic stromal cells;RSC Chemical Biology;2024